Group 4A: HER2+ Breast Cancer; Antibody-drug Conjugates; Brain Metastasis; Clinical Trials; Novel Targets & Therapies

Poster #1041: Preclinical and early clinical data of ZN-1041 in combination with trastuzumab deruxtecan to treat breast cancer with or without CNS metastases

Poster #1044: Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER2-positive breast cancer (BC): Updated results from a phase 1b/2 study